Pembrolizumab as second-line therapy for advanced urothelial carcinoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Programmed Cell Death 1 Receptor
  • Urologic Neoplasms

abstract

  • Pembrolizumab was associated with significantly longer overall survival (by approximately 3 months) and with a lower rate of treatment-related adverse events than chemotherapy as second-line therapy for platinum-refractory advanced urothelial carcinoma. (Funded by Merck; KEYNOTE-045 ClinicalTrials.gov number, NCT02256436 .).

publication date

  • March 16, 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC5635424

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1613683

PubMed ID

  • 28212060

Additional Document Info

start page

  • 1015

end page

  • 1026

volume

  • 376

number

  • 11